Jun 16, 2026Cardiovascular

Sacubitril/Valsartan in HFpEF: Biomarker Win, Function Gap

Sacubitril/valsartan lowers NT-proBNP in HFpEF, but does it improve symptoms or walking? A close look at trials, safety, and competing drugs.

sacubitril/valsartanhfpefhfmrefnt-probnp

Read article →

Jun 16, 2026Metabolic Therapeutics

GLP-1 vs. SGLT2: Which Cardiorenal Benefit Matters Most?

GLP-1 receptor agonists and SGLT2 inhibitors can retain benefits together, but kidney, heart-failure, stroke, and MACE evidence differs.

glp-1 receptor agonistssglt2 inhibitorscardiorenal outcomesmace

Read article →

Mar 28, 2026Cardiovascular Health

How SGLT2 Inhibitors Protect Failing Hearts Beyond Blood Sugar

SGLT2 inhibitors cut heart-failure risk beyond glucose control. What trials, remodeling data, mechanisms, safety limits, and cardio-oncology gaps show.

sglt2 inhibitorsautophagyheart failureampk

Read article →

Mar 28, 2026Nutrition

CoQ10 for Heart Failure: A Mortality Signal, Not Proof

CoQ10 reduced mortality and heart-failure hospitalizations in a review of trials. Why one promising signal still falls short of proven therapy.

coq10heart failuresupplementationmortality

Read article →

Mar 28, 2026Gut Microbiome

Gut Dysbiosis and Heart Failure: What IPA Evidence Shows

Gut dysbiosis tracks with heart failure across studies. TMAO has human data; indole-3-propionic acid remains a mitochondrial hypothesis.

gut microbiomealpha diversitydysbiosisheart failure

Read article →

Mar 27, 2026Nutrition

Why NAD+ Supplements May Miss the Problem in Diabetic Hearts

New diabetic-heart research links ACMSD to impaired NAD+ synthesis, while the only heart-failure NAD+ trial leaves HFpEF treatment unanswered in humans.

nad+heart failurehfpefglp-1 agonists

Read article →

Mar 27, 2026Nutrition

NAD+ and Heart Failure: Why SIRT3 May Not Be the Answer

NR and NMN raise blood NAD+ in humans, but cardiac benefits remain unproven—and mouse data challenge the usual SIRT3 explanation.

nad+nmnsirt3heart failure

Read article →

Mar 27, 2026Cardiovascular Health

GLP-1 Drugs and Heart Failure: What an NNT of 80 Means

GLP-1 drugs reduce heart failure events modestly overall, with stronger signals in obesity. See what the NNTs, limits, and next-generation drugs mean.

glp-1 agonistssemaglutidetirzepatideheart failure

Read article →

Mar 23, 2026Cardiovascular Health

HFpEF Exercise: What Training Can—and Cannot—Do

HFpEF exercise training improves fitness and quality of life, but evidence does not yet show fewer deaths or hospitalizations. Here's what the trials show.

hfpefsglt2 inhibitorsheart failurefinerenone

Read article →

Mar 17, 2026Cardiovascular Health

Semaglutide Helps a Specific Kind of HFpEF—Not All

Semaglutide improved symptoms and walking capacity in obesity-related HFpEF, but the evidence does not support cardiac use for every patient—or biohacker.

heart failurehfpefsemaglutideejection fraction

Read article →

Mar 1, 2026Cardiovascular Health

GLP-1s Cut Heart Failure Risk Only in Obesity

GLP-1 drugs lower cardiovascular death broadly, but heart failure hospitalization benefit appears limited to obesity-driven disease.

glp-1heart failureobesityhfpef

Read article →

Feb 28, 2026Cardiovascular Health

GLP-1 Drugs in Obese Heart Failure: Where the Benefit Is

A 2025 meta-analysis suggests GLP-1 drugs help some obese heart failure patients, but the signal looks strongest in HFpEF, not HFrEF.

semaglutideglp-1 agonistsheart failurehfpef

Read article →

Page 1 of 2Next →